Today's health news ranges from major maternity service failures in the UK to clinical advances in dermatitis care, cancer treatment, and preventive medicine, while highlighting concerning gaps in infectious disease management and antibiotic stewardship.

Donna Ockenden's 3-year review of Nottingham University Hospitals reveals a bullying culture and systemic failures in maternity services that led to the needless deaths and serious harm of over 500 mothers and babies, representing one of the UK's most significant healthcare scandals.

Virtual care proves equally effective as in-person visits for atopic dermatitis management, with a team-based online model delivering equivalent symptom improvements over 12 months, potentially expanding access to dermatological care.

A new FDA policy restricts access to a cost-effective, potentially lifesaving therapy for children and severely ill patients with Clostridioides difficile infections, creating a major clinical setback in treating this serious bacterial infection.

NICE has endorsed cemiplimab as a treatment option for patients with recurrent or metastatic cervical cancer who have exhausted platinum-based chemotherapy regimens, offering a new immunotherapy alternative.

Veterans Affairs healthcare facilities are prescribing antibiotics for simple diverticulitis cases, contradicting a decade-old American Gastroenterological Association guideline that restricts antibiotic use to select patient populations only.

PCR testing demonstrates particular value in detecting infections among lung transplant recipients when combined with imaging studies, improving diagnostic accuracy in this vulnerable population.

Initiating statin therapy is associated with reduced frailty risk in older adults, including those with prefrailty at baseline, suggesting cardiovascular medications may offer additional protective benefits beyond heart disease prevention.

Patients with type 2 diabetes who develop urinary or genital tract infections after starting SGLT2 inhibitors are significantly more likely to discontinue the diabetes medication, potentially compromising long-term glycemic control.